Publication Name	World Journal of Clinical Cases
Manuscript ID	73331
Country	China

Received	2022-03-05 04:32
Peer-Review Started	2022-03-05 04:34
To Make the First Decision
Return for Revision	2022-03-27 17:08
Revised	2022-03-30 17:35
Second Decision	2022-07-01 03:09
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2022-07-06 03:36
Articles in Press	2022-07-06 03:36
Publication Fee Transferred
Edit the Manuscript by Language Editor	2022-06-28 02:17
Typeset the Manuscript	2022-07-22 02:56
Publish the Manuscript Online	2022-08-01 09:20

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Clinical Trials Study
Article Title	Role of H2 receptor blocker famotidine over the clinical recovery of COVID-19 patients: A randomized controlled trial
Manuscript Source	Unsolicited Manuscript
All Author List	Abu Taiub Mohammed Mohiuddin Chowdhury, Aktar Kamal, Md Kafil Uddin Abbas, Md Rezaul Karim, Md Ahsan Ali, Shubhashis Talukder, H M Hamidullah Mehedi, Hamid Hassan, Abul Hossain Shahin, Ya-Rui Li and Shui-Xiang He
ORCID	Author(s) ORCID Number Abu Taiub Mohammed Mohiuddin Chowdhury http://orcid.org/0000-0002-2054-1424 Aktar Kamal http://orcid.org/0000-0002-4713-7421 Md Kafil Uddin Abbas http://orcid.org/0000-0003-3548-9398 Md Rezaul Karim http://orcid.org/0000-0001-9697-4907 Md Ahsan Ali http://orcid.org/0000-0003-0695-0667 Shubhashis Talukder http://orcid.org/0000-0002-4526-3707 H M Hamidullah Mehedi http://orcid.org/0000-0001-6683-6773 Hamid Hassan http://orcid.org/0000-0002-0721-7363 Abul Hossain Shahin http://orcid.org/0000-0003-0523-8352 Ya-Rui Li http://orcid.org/0000-0001-9371-7622 Shui-Xiang He http://orcid.org/0000-0003-3396-5653
Funding Agency and Grant Number
Corresponding Author	Shui-Xiang He, PhD, Professor, Department of Gastroenterology, The First affiliated hospital of Xi’an Jiaotong University, Yanta Road, Xi'an 710061, Shaanxi, China. dyyyjxk@mail.xjtu.edu.cn
Key Words	COVID-19; SARS-Cov-2; Famotidine; COVID-19 acute respiratory distress syndrome; COVID-19 treatment; Bangladesh
Core Tip	Treatment with famotidine demonstrated a comparatively better outcome in the survival rates of patients. A rapid recovery time, less duration of intensive care unit (ICU) stay among the survivors, favorable improvement in the computed tomography findings and an earlier viral clearance were observed in the famotidine treatment group which differ significantly in a t-test (P ≤ 0.05). The difference between the time to symptomatic recovery, ICU stay duration and the national early warning score-2 on discharge was not significant however, mean values were relatively less than the control. Nevertheless, survival benefit was not significant with the famotidine as an added treatment for severe coronavirus disease 2019.
Publish Date	2022-08-01 09:20
Citation	Mohiuddin Chowdhury ATM, Kamal A, Abbas MKU, Karim MR, Ali A, Talukder S, Hamidullah Mehedi HM, Hassan H, Shahin AH, Li YR, He SX. Role of H2 receptor blocker famotidine over the clinical recovery of COVID-19 patients: A randomized controlled trial. World J Clin Cases 2022; 10(23): 8170-8185
URL	https://www.wjgnet.com/2307-8960/full/v10/i23/8170.htm
DOI	https://dx.doi.org/10.12998/wjcc.v10.i23.8170

Full Article (PDF)	WJCC-10-8170.pdf
Full Article (Word)	WJCC-10-8170.docx
CONSORT 2010 Statement	73331-CONSORT-2010-Statement-revision.pdf
Manuscript File	73331_Auto_Edited-HZ-Filipodia-LS.docx
Answering Reviewers	73331-Answering reviewers.pdf
Audio Core Tip	73331-Audio core tip.wma
Biostatistics Review Certificate	73331-Biostatistics statement.pdf
Clinical Trial Registration Statement	73331-Clinical trial registration statement.pdf
Conflict-of-Interest Disclosure Form	73331-Conflict-of-interest statement.pdf
Copyright License Agreement	73331-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s)	73331-Informed consent statement.pdf
Institutional Review Board Approval Form or Document	73331-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	73331-Language certificate.pdf
Peer-review Report	73331-Peer-review(s).pdf
Scientific Editor Work List	73331-Scientific editor work list.pdf